NCT01933256View on ClinicalTrials.gov

Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

HIP2B

DRUG

Placebo

Trial Locations (1)

91911

Profil Institute for Clinical Research, Inc., Chula Vista

Sponsors

Lead Sponsor

CureDM
All Listed Sponsors
collaborator

Profil Institute for Clinical Research, Inc.

OTHER

lead

CureDM

INDUSTRY

NCT01933256 - Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin | Biotech Hunter | Biotech Hunter